Resistant Hypertension: A Real Entity or a Phantom Diagnosis?

Overview

Journal J Clin Hypertens (Greenwich)

Specialty Cardiology & Vascular Diseases

Date 2015 Apr 21

PMID 25891442

Citations 3

Authors

Costas Thomopoulos

George Skalis

Thomas Makris

Affiliations

Soon will be listed here.

Citing Articles

Pharmacogenomics of amlodipine and hydrochlorothiazide therapy and the quest for improved control of hypertension: a mini review.

Johnson R, Dludla P, Mabhida S, Benjeddou M, Louw J, February F Heart Fail Rev. 2019; 24(3):343-357.

PMID: 30645721 PMC: 6476827. DOI: 10.1007/s10741-018-09765-y.

Resistant Hypertension: A Real Entity Requiring Special Treatment?.

Taddei S, Bruno R Eur Cardiol. 2018; 11(1):8-11.

PMID: 30310440 PMC: 6159429. DOI: 10.15420/ecr.2016.11.1.

Cystatin C, vascular biomarkers and measured glomerular filtration rate in patients with unresponsive hypertensive phenotype: a pilot study.

Cabarkapa V, Ilincic B, deric M, Vucaj Cirilovic V, Kresoja M, Zeravica R Ren Fail. 2016; 39(1):203-210.

PMID: 27876431 PMC: 6014334. DOI: 10.1080/0886022X.2016.1256316.

References

Bohm M, Mahfoud F, Ukena C, Hoppe U, Narkiewicz K, Negoita M . First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension. 2015; 65(4):766-74. DOI: 10.1161/HYPERTENSIONAHA.114.05010. View

Sandler G, LEISHMAN A, Humberstone P . Guanethidine-resistant hypertension. Circulation. 1968; 38(3):542-51. DOI: 10.1161/01.cir.38.3.542. View

Calhoun D, Jones D, Textor S, Goff D, Murphy T, Toto R . Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008; 117(25):e510-26. DOI: 10.1161/CIRCULATIONAHA.108.189141. View

Tsioufis C, Kasiakogias A, Kordalis A, Dimitriadis K, Thomopoulos C, Tsiachris D . Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study. J Hypertens. 2013; 32(2):415-22. DOI: 10.1097/HJH.0000000000000023. View

Chow C, Teo K, Rangarajan S, Islam S, Gupta R, Avezum A . Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013; 310(9):959-68. DOI: 10.1001/jama.2013.184182. View

Wilson M, Morgan T, Gillies A . A role of frusemide in resistant hypertension. Med J Aust. 1977; 1(7):213-5. DOI: 10.5694/j.1326-5377.1977.tb130634.x. View

Boswell L, Pascual J, Oliveras A . Resistant hypertension: do all definitions describe the same patients?. J Hum Hypertens. 2015; 29(9):530-4. DOI: 10.1038/jhh.2014.128. View

Hall D, Charocopos F, Froer K, Rudolph W . Use of minoxidil in resistant hypertension. Beneficial effects, adverse reactions and indications. Herz. 1978; 3(5):313-24. View

Persson G, Ekwall B, Furst C . A clinical trial of guanoxan (Envacar) in hypertension resistant to common drugs. Acta Med Scand. 1967; 182(5):567-74. DOI: 10.1111/j.0954-6820.1967.tb10882.x. View

10.

GIFFORD Jr R, TARAZI R . Resistant hypertension: diagnosis and management. Ann Intern Med. 1978; 88(5):661-5. DOI: 10.7326/0003-4819-88-5-661. View

11.

Thomopoulos C, Parati G, Zanchetti A . Effects of blood pressure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular risk--overview and meta-analyses of randomized trials. J Hypertens. 2014; 32(12):2305-14. DOI: 10.1097/HJH.0000000000000380. View

12.

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M . 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31(7):1281-357. DOI: 10.1097/01.hjh.0000431740.32696.cc. View

13.

Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, Fusi V . High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens. 2001; 19(11):2063-70. DOI: 10.1097/00004872-200111000-00018. View

14.

Chobanian A, Bakris G, Black H, Cushman W, Green L, Izzo Jr J . The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289(19):2560-72. DOI: 10.1001/jama.289.19.2560. View

15.

Dargie H, Dollery C, Daniel J . Labetalol in resistant hypertension. Br J Clin Pharmacol. 1976; 3(4 Suppl 3):751-5. View

16.

Parving H, Brenner B, McMurray J, de Zeeuw D, Haffner S, Solomon S . Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012; 367(23):2204-13. DOI: 10.1056/NEJMoa1208799. View

17.

Alderman M, Cohen H, Sealey J, Laragh J . Pressor responses to antihypertensive drug types. Am J Hypertens. 2010; 23(9):1031-7. DOI: 10.1038/ajh.2010.114. View